Current Trials

These are some of the clinical trials that GLCC are currently working on. Together with our clients, we strive to deliver the most efficient and cost-effective services.

Device

  • RESDIO AP

    • Device
    • PHASE
    • 300 participants
    • 4 sites in New Zealand
    • 1 site in Australia

    Randomised Controlled Trial Evaluating Safety of Device Implantation in Orally Anticoagulated Patients (RESDIO-AP trial).

    A randomised, single-blinded, controlled trial comparing device implantation in patients with therapeutic levels of anticoagulation (INR 2.0-3.0) to those with an INR <1.5 at the time of the surgical procedure.

    This is a randomised, single blinded, controlled trial comparing device implantation in participants with therapeutic levels of anticoagulation (INR 2.0-3.0) to those with an INR <1.5 at the time of the surgical procedure. The purpose of this study is to prospectively evaluate the safety and efficacy of device implantation in patients with therapeutic levels of anticoagulation (INR 2.0-3.0) in a multi-centre randomised controlled trial. The study is to be conducted at 5 centres located in NZ and Australia.

    More about the RESDIO AP study

Trial Types

Our People

At GLCC we strongly believe people are our biggest asset. Together with support from national and international academia, research registrars and fellows, we are dedicated to achieving the highest possible standard in clinical research.

Benefits of conducting trials in New Zealand

  • Well established clinical trial infrastructure
  • Excellent recruitment and retention rates
  • High standard of medical practice
  • High standard of clinical trial data
  • Adherence to ICH/GCP and FDA regulations
  • Regulatory framework based on European and American systems

Learn more about conducting clinical trials in New Zealand